Dasatinib Inhibits Lung Cancer Cell Growth and Patient Derived Tumor Growth in Mice by Targeting LIMK1

Dasatinib Inhibits Lung Cancer Cell Growth and Patient Derived Tumor Growth in Mice by Targeting LIMK1

Lung cancer is a leading cause cancer-related death with diversity. A promising approach to meet the need for improved cancer treatment is drug repurposing. Dasatinib, a second generation of tyrosine kinase inhibitors (TKIs), is a potent treatment agent for chronic myeloid leukemia (CML) approved by...

Full description

Bibliographic Details
Main Authors: Man Zhang, Jie Tian, Rui Wang, Mengqiu Song, Ran Zhao, Hanyong Chen, Kangdong Liu, Jung-Hyun Shim, Feng Zhu, Zigang Dong, Mee-Hyun Lee
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
LIMK1
dasatinib
non-small cell lung cancer
off-targets
patient-derived xenografts
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2020.556532/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2020.556532/full

Similar Items